Expanding epidemic. Unmet medical need. Enormous market potential.


Where will innovation come from in the metabolic drug pipeline? What clinical strategies will satisfy regulators?

Answering these questions holds the key to dominating the enormous and expanding cardiometabolic market.

Continuing unmet medical need, bottlenecks in the pipeline and a harsh regulatory climate remain strong drivers for enhancing your metabolic drug development strategy.

By giving you unparalleled access to the minds behind the most promising drugs in development, Metabolic Disease Drug Development will provide the perfect platform to address these concerns and direct your preclinical and clinical development strategy.

Metabolic Disease Drug Development guarantees strong representation and candid discussion from senior level figures at Pfizer, Merck, BMS and the most innovative biotechs in the field. It will provide valuable insight into identifying and validating new metabolic drug targets, streamlining clinical strategy and speeding the passage of your drugs to market.

Don’t miss this opportunity to explore how your competitors and future collaborators are reinvigorating their metabolic drug pipeline:

  • Get the latest from the most exciting biotechs in the field on innovations in novel drug targets
  • Uncover how Merck are rationalizing their metabolic drug development strategy to maximize profit
  • Benchmark your clinical strategy against the industry gold standard by hearing from Roche
  • Get unparalleled insight into how regulatory guidelines have directed the development of Lixisenatide with Sanofi
  • Explore how Janssen are integrating the basic and clinical sciences to develop novel SGLT2 inhibitors
  • Learn how Boehringer-Ingelheim, Daiichi Sankyo and Pfizer are placing increased emphasis on external collaborations with biotechs and academia
  • Discover how clinician Steven Smith mitigates against cardiovascular risk and attains an excellent risk: benefit profile
  • Hear how Sanofi and Janssen are exploring new areas in dyslipidemia pharmacotherapy

Who should attend this meeting:

Drug developers focusing on developing novel metabolic drugs

Scientists and academics working in diabetes, obesity and dyslipidemia

Clinicians and CROs specializing in metabolic drug trials